Wednesday, June 19, 2013

Dekavil at the EULAR 2013



I’ve seen a poster on dekavil at the EULAR 2013 meeting. Let’s return to the ACR 2012 meeting for a moment. I’d written:
“Maybe we have to wait for a couple of years to evaluate dekavil. If the results are as good as shown in the abstract, then it could develop into a block buster. Philogen S.p.A. hasn’t rushed yet to large scale international multicenter studies and I interpret this as a hint, that the potential of this drug isn’t as high as the study of M. Galeazzi wants us to believe.”

M. Galeazzi and colleagues presented [SAT0108]: Dekavil (F8-IL10): a novel anti-inflammatory immunocytokine for the treatment of rheumathoid arthritis”. Conclusions: “The promising safety data regarding the clinical use of F8-IL10, together with preliminary positive signs of activity, suggest that the targeted delivery of IL10 to the site of inflammation may be beneficial to patients with RA. These results also warrant future developments of the product in randomized clinical trials. An update of clinical data will be presented.”

That’s not so different from the text presented at the ACR 2012: “The promising safety data regarding the clinical use of F8-IL10, together with preliminary positive signs of activity may be favored by the targeted delivery of IL10 to the site of inflammation. These results also warrant future developments of the product in randomized clinical trials, which are currently in planning. An update of clinical data will be presented at the ACR meeting.”
Please promise to publish more than promising data at the ACR 2013 at the next ACR meeting.

Links:

http://rheumatologe.blogspot.de/2012/12/dekavil-at-acr-2012-in-washington.html
http://rheumatologe.blogspot.de/2012/07/dekavil-at-eular-2012.html


Fostamatinib at the EULAR 2013



Concerning fostamatinib I had grown suspicious if it will come to market at all.

EULAR 2012: “It looks a bit too good not to cause suspicion, not in the results but in the relevance. I think we should look careful at the results of the studies that are to come in the next two years. Larger numbers of patients in phase 2 studies would make me more confident that fostamatinib may become a useful drug in the treatment of rheumatoid arthritis.”
ACR 2012, after I had to look at a rodent study: “And there has been nothing more at the ACR 2012 meeting! Perhaps asking for a date, when fostamatinib is to be launched, was a bit premature. I ask myself if there really is any drug in sight!”

Any new developments at the EULAR 2013 to get less suspicious?

There has been a study, one study. P. C. Taylor and colleagues presented [OP0048]: “OSKIRA-4: a phase IIb randomised, placebocontrolled study of the efficacy and safety of fostamatinib monotherapy”. Objectives were the efficacy of fostamatinib monotherapy compared with placebo and the assessment of non-inferiority of fostamatinib to Adalimumab. Two study arms of fostamatinib were superior to placebo, but one wasn’t. All three fostamatinib arms were inferior to adalimumab. The authors argue: “However, the performance of ADA monotherapy in this trial was at the upper end of that observed in previous studies. Fosta is being evaluated in combination with DMARDs in the ongoing Phase III programme.” If I choose to run a 100 m sprint against Donovan Bailey and loose, I can’t argue that he was exceptional quick this day.

The suspicion reaches maximum proportions. We must ask the people in charge if it’s still ethical to continue the phase III study as up to 27% diarrhoea as well as other adverse events may harm the patients, who take part in the trial. I don’t think that FDA or EMEA will approve a drug with such a weak effect and side effects nowadays.

PS. OT: I wouldn’t have approved anakinra for the indication rheumatoid arthritis!

Links:
http://rheumatologe.blogspot.de/2012/07/fostamatinib-at-eular-2012.html
http://rheumatologe.blogspot.de/2012/12/fostamatinib-at-acr-2012-in-washington.html

PPS. Just got a post on Twitter by Philip Gardiner ‏@PhilipGardiner : AstraZeneca has already dropped the fostacitinib! http://www.pmlive.com/pharma_news/astrazeneca_drops_arthritis_candidate_fostamatinib_481092

Tuesday, June 18, 2013

NNC0109-0012 (anti-IL-20 MAB) at the EULAR 2013



I had written about the novel anti-IL-20 MAB (NNC0109-0012) coming from last year’s ACR in Washington. NNC0109-0012 is a novel human monoclonal IgG4 antibody which binds to IL-20. Here’s the old story: http://rheumatologe.blogspot.de/2012/12/nnc0109-0012-at-acr-2012-in-washington.html.

Let’s switch to the 2013 meeting of EULAR in Madrid. There have been two posters/abstracts.

A. L. Blasius and colleagues, all working for Nordisk, published a study [AB0036]: “IL-20 targets local tissue inflammation as opposed to systemic inflammation”. Conclusions: “Using a variety of methods, no evidence could be found in support of a role for IL-20 in systemic immune responses. This is consistent with the hypothesis that IL-20 acts predominantly at local sites of inflammation.”

L. Senolt and colleagues presented a study [SAT0112]: “Improvements in patient-reported physical function, pain and global disease activity in patients with rheumatoid arthritis after treatment with NNC0109-0012 (anti-IL-20 MAB) in a phase 2a trial”. Conclusions: “12-weeks treatment with 3 mg/kg NNC0109-0012 effectively improved physical function, pain and global disease activity in RF- and ACPA positive patients with RA on stable MTX. These improvements were clinically relevant and sustained when measured at the end of the 13 weeks follow-up.”
Let’s compare this study and the study presented at the ACR.
Methods (EULAR 2013): “67 patients with active RA and inadequate responses to MTX were randomised to 12 once-weekly doses of 3mg/kg NNC0109-0012 (n=45) or placebo (n=22) and stable background MTX, and then followed for an additional 13 weeks. Of the 67 randomised patients 43 were Rheumatoid Factor [RF]- and anti-citrullinated peptide antibody [ACPA]-positive.”
Methods (ACR 2012): “A total of 67 RA patients (51 females:16 males) with active disease (DAS28 (CRP) _4.5, _5 swollen and _5 tender joints) were randomized in a 2:1 ratio (45 NNC0109-0012: 22 placebo) in a multicenter, double-blind, placebo-controlled, parallel group trial.”

If we see the same study again next ACR in newer evaluation and wording, it should be clear that “something is rotten in the state of Denmark” – sorry Nordisk, I couldn’t resist!

I’m less optimistic about NNC0109-0012 than I had been post ACR 2012. And I repeat: Nordisk - how about naming the child? It would make discussions easier and show commitment.

Brodalumab at the EULAR 2013



If I look at what I’ve written half a year ago concerning brodalumab, I guess, I’ve been quite right: http://rheumatologe.blogspot.de/2012/12/brodalumab-at-acr-2012-in-washington.html. “I think brodalumab is a dead end for rheumatoid arthritis though it might be useful in other diseases.” There has been just one study on brodalumab in the treatment of psoriatic arthritis as it targets IL-17, which plays a role "in the pathogenesis and ongoing inflammation of psoriatic disease".

P. J. Mease and colleagues presented the following study [OP0103]: “Efficacy of brodalumab, an anti-il-17r antibody, in subjects with psoriatic arthritis”. In results we read: “ACR20 was achieved at week 12 by 37% and 39% of subjects in the 140- and 280-mg brodalumab groups, respectively, compared with 18% of subjects in the pbo group (p < .05).” Conclusions: “Brodalumab treatment was associated with significant clinical response and acceptable safety profile in subjects with PsA.”

The ACR20 response isn’t very high, but nevertheless there’s a significant difference between placebo and brodalumab in both dosings. So I agree with the authors, that brodalumab warrants further evaluation for treatment of psoriatic arthritis.



ALX-0061 / ANTI-IL-6 RECEPTOR NANOBODY® at the EULAR 2013



Two studies on the novel anti-IL-6 receptor nanobody® (ALX-0061) had been presented at the ACR 2012 meeting in Washington; http://rheumatologe.blogspot.de/2012/12/alx-0061-at-acr-annual-meeting-2012-in.html. At the EULAR meeting 2013 in Madrid we’ll get two more studies to discuss.

J.-B. Holz and colleagues presented a study [OP0043]: “Twenty-four weeks of treatment with a novel anti-il-6 receptor nanobody® (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/II study in RA”. Conclusions: “In patients with active RA, rapid and strong effects on the IL-6 pathway were observed and associated with a strong clinical response. Clinically significant improvement of disease activity occurred fast and almost 60% of patients achieved state of remission at the end of 24 weeks. The treatment was well tolerated at all doses …”. ACR20 84%, ACR50 68%, ACR70 52% sounds too good. The AMBITION study resulted in: ACR20 70%, ACR50 44%, ACR70 28%. I think future results for ALX-0061 will look more realistic to be comparable to real life.

M. Van Roy and colleagues presented the following study [FRI0021]: “ALX-0061, an anti-IL-6R nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab“. Conclusions: “ALX-0061 demonstrates in vitro a preferential biological activity profile for sIL-6R with a lesser activity for mIL-6R, while TCZ has a higher preference for mIL-6R. Preferential inhibition of sIL-6R trans-signalling by ALX-0061 could provide superior therapeutic efficacy with a better side effect profile than TCZ.”

There seems to be a lot of optimism within the research teams! But compared with the results of some small molecules I’m tempted to share this optimism. I’m looking forward to see larger studies on ALX-0061!



Pateclizumab at the EULAR 2013



Pateclizumab is an anti-lymphotoxin-alpha monoclonal antibody (the artist formely known as MLTA3698A). I hadn’t seen anything at the EULAR 2012 in Berlin. As I hadn't seen anything at the ACR 2012 in Washington, I thought to wait until the EULAR 2013 before I'd erase pateclizumab from my list of interests.
Now there have been two studies on Pateclizumab at the EULAR 2013 in Madrid.

A. E. Herman and colleagues presented a study [FRI0170]: "Pharmacodynamic biomarkers demonstrate overlapping and distinct biological pathways for lymphotoxin-αlpha and tumor necrosis factor-alpha in patients with rheumatoid arthritis". Within their conclusion you find this sentence: "LTα blockade demonstrated significant reduction in levels of CCL19, as well as CXCL13, suggesting an impact on T and B cell migration and/or lymphogenesis. However, the decrease in chemokines observed with LTα blockade was associated with only modest reduction in clinical activity (5)."
Not too overwhelming, I'd say.

But there has been a second study by W. Kennedy and colleagues [SAT0110]: "Efficacy and safety of pateclizumab (antilymphotoxin-alpha) in dmard-ir patients: results of a randomized, double-blind, placebo-controlled head-to-head phase 2 study with adalimumab". In their conclusion the authors state: "Pateclizumab treatment of DMARD-IR RA patients was associated with modest improvement in the signs and symptoms of RA, and was inferior to adalimumab after 12 weeks of treatment."

I don't think that pateclizumab will make it to the market as the demand for modest improvement isn't too big with better alternative options already in use. I'm a bit disappointed as two years ago I thought targeting lymphotoxin-αlpha could be an interesting approach. I guess we'll have to wait if pateclizumab is abandoned silently.



Monday, June 17, 2013

EULAR 2013 Meeting in Madrid – from the social and sightseeing perspective


The Long March or the Hard Road to Madrid
I started very early in the morning, in fact I got up at 4:30 a.m. to catch my plane to Madrid. Because of the air traffic controllers’ strike in France the flight had been cancelled. I queued for about three hours and got a flight via London. In the afternoon I went to London Heathrow, was assigned to use the fast track, reached the gate, only to get informed, that the personal there was waiting (and with them the passengers) for the crew to reach London to start boarding. After another 2 ½ hours of gruelling waiting, we made it into the plane. The flight was taking longer than usual as we circumnavigated France. I reached Madrid in the evening and took a taxi the meeting point of our tweetup. But there was nobody left there. I tried grabbing another taxi, and who just got of the taxi? David OReilly (‏@Rheuma_suffolk)! So we had our very late tweetup with a beer.




The Hardships aren’t over
The next day I found out that I’ve messed up with my twitter password. When I started writing about North Korea, I got a little paranoid about my blog and my twitter account being hacked. I devised a very long password (above 30 digits), and must have spelled it wrong twice. I could access my blog, but I couldn’t enter the twitterworld. I’ve just corrected the twitter password to the blog password. I missed tweeting from the congress very much.

The Salvage Tweetup
I’ve always supported the idea of a second tweetup option. Thanks to Irwin Lim (@_connectedcare) we had a second meeting at the INTERVIEW ROOM, MEZZANINE Hall 10 on Friday midday. I’ve liked to see you all:
Carlo V Caballero ‏@carvicab
Dr Irwin Lim ‏@_connectedcare
Dr. shashank akerkar ‏@doctorakerkar
Dr Ai Lyn Tan ‏@DrAiLynTan
Jose Campos ‏@JoseCamposMD
mrreutt ‏@matylda68
Emma Leah @NatRevRheumatol
Philip Robinson ‏@philipcrobinson
David OReilly ‏@Rheuma_suffolk
Michiel Zandbelt ‏@zandbelt
and more [please help me to complete the list – there were Lauren, Seth … who else?].



It has been interesting to look from the press window into the exhibit hall, but only for the picture, because we were busy talking. A wonderful reunion stretching from Australia and India, as well as both Americas and of cause Germany, Poland, Spain, and UK.
I hope that we and others, who want to join our informal round, will meet again at the next meetings (ACR 2013 in San Diego, EULAR 2014 in Paris). And hopefully my plane will be on time.
Thanks to the ones, who planned and organized the two tweetups.



 
At the Meeting


We were guarded by bears, actually a common form of sweets in Germany look like these bears.


There has been flamenco in the exhibition hall.

Sightseeing
Yes, I also could set apart some time for sightseeing. I have been to Madrid several times, but most of the times just for a day, so I have been lucky to see at least something.


Relaxing at the lake


Looking at a demostration against capital punishment - I nearly joined them. Only time restrictions kept me from doing so.



And then there was this beautiful old building on fire. Even TV reporters were on the scene.



A quick look or two at the Retiro



Cibeles

A church


The royal palace